CRISPR Therapeutics AG Stock (CRSP) - Quote Nasdaq- MarketScreener (2024)

CRISPR THERAPEUTICS AG

Add to a list

To use this feature you must be a member

Log inSign up

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
55.03 ^USD	+3.38%		+3.61%	-12.09%

Jun. 11	Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
May. 23	CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer	MT

Financials (USD)

Sales 2024 *	79.35M	Sales 2025 *	331M	Capitalization	4.67B
Net income 2024 *	-450M	Net income 2025 *	-393M	EV / Sales 2024 *	35.1x
Net cash position 2024 *	1.89B	Net cash position 2025 *	1.64B	EV / Sales 2025 *	9.18x
P/E ratio 2024 *	-9.88x	P/E ratio 2025 *	-12.3x	Employees	407
Yield 2024 *	-	Yield 2025 *	-	Free-Float	97.94%

More Fundamentals * Assessed data

Chart CRISPR Therapeutics AG

Duration

Period

Style

Latest news about CRISPR Therapeutics AG

Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM	Jun. 11
CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer	May. 23	MT
CRISPR Therapeutics Announces Executive Changes	May. 23	CI
Transcript : CRISPR Therapeutics AG Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM	May. 15
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating	May. 10	MT
Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating	May. 09	MT
Needham Adjusts Price Target on CRISPR Therapeutics to $88 From $90, Keeps Buy Rating	May. 09	MT
Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating	May. 09	MT
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q1 Revenue $504,000	May. 08	MT
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach	May. 08	CI
Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	Apr. 18	MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	Apr. 17	MT
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating	Mar. 06	MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating	Feb. 26	MT

More news

Latest transcript on CRISPR Therapeutics AG

CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM

Jun. 11

More transcripts

Analyst Recommendations on CRISPR Therapeutics AG

Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating	May. 10	MT
Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating	May. 09	MT
Needham Adjusts Price Target on CRISPR Therapeutics to $88 From $90, Keeps Buy Rating	May. 09	MT
Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating	May. 09	MT
Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	Apr. 18	MT

More recommendations

Press releases CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences	May. 29	AQ
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments	May. 23	AQ
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference	May. 09	AQ
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	May. 08	AQ
CRISPR Therapeutics : ASGCT 2024 Oral Presentation	May. 08	PU

More press releases

News in other languages on CRISPR Therapeutics AG

Vertex y Crispr comercializarán un tratamiento de 2,2 millones de dólares para la anemia falciforme	Dec. 12
Vertex et Crispr vont commercialiser un traitement à 2,2 M$ contre la drépanocytose	Dec. 11
En Direct des Marchés : LVMH, Saint-Gobain, Casino, Manitou, Cigna, Macy's, Pharnext...	Dec. 11
EN DIRECTO DESDE LOS MERCADOS: Nvidia, Microsoft, RWE, LVMH, Apple, Boeing, Tesla, Cigna, Macy's, Uniper, Pharnext...	Dec. 11
Schweizer Crispr und Vertex erhalten FDA-Zulassung für erste Sichelzelltherapie	Dec. 08

More news

Quotes and Performance

1 day	+3.38%
1 week	+3.61%
Current month	+1.89%
1 month	-4.91%
3 months	-15.59%
6 months	-12.13%
Current year	-12.09%

More quotes

Highs and lows

1 week

52.31

55.15

1 month

52.31

67.88

Current year

51.02

Managers and Directors - CRISPR Therapeutics AG

Managers	Title	Age	Since
Samarth Kulkarni CEO	Chief Executive Officer	45	15-07-31
Raju Prasad DFI	Director of Finance/CFO	40	23-03-13
Stephen Kennedy CTO	Chief Tech/Sci/R&D Officer	67	19-09-30

Members of the board	Title	Age	Since
Doug Treco Treco BRD	Director/Board Member	66	20-06-10
Simeon George BRD	Director/Board Member	47	15-04-28
Ali Behbahani BRD	Director/Board Member	45	15-03-31

More insiders

ETFs positioned on CRISPR Therapeutics AG

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	10.82%	208 M€	+14.51%	-
	8.55%	2 M€	-25.75%
LEVERAGE SHARES -3X SHORTARKINNOVATION ETP SECURITIES - USD	4.84%	1 M€	0.00%	-
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD	4.53%	1 M€	0.00%	-

More ETFs positioned on CRISPR Therapeutics AG

Quotes

Date	Price	Change	Volume
24-07-09	55.03	+3.38%	904,889
24-07-08	53.23	+0.24%	1,051,596
24-07-05	53.1	-1.48%	1,078,291
24-07-03	53.9	+1.48%	679,450
24-07-02	53.12	-1.55%	1,058,986

Delayed Quote Nasdaq, July 09, 2024 at 04:00 pm EDT

More quotes

Company Profile

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Sector

Calendar

2024-07-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CRISPR Therapeutics AG

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

55.03USD

Average target price

86.57USD

Spread / Average Target

+57.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

	1st Jan change	Capi.
CRISPR THERAPEUTICS AG	-12.09%	4.67B
MODERNA, INC.	+16.71%	44.48B
LONZA GROUP AG	+43.45%	40.57B
IQVIA HOLDINGS INC.	-7.92%	38.82B
ALNYLAM PHARMACEUTICALS, INC.	+33.09%	32.22B
CELLTRION, INC.	-7.10%	27.84B
ICON PUBLIC LIMITED COMPANY	+14.46%	26.79B
UNITED THERAPEUTICS CORPORATION	+46.73%	14.31B
MEDPACE HOLDINGS, INC.	+34.07%	12.7B
BIO-TECHNE CORPORATION	-7.61%	11.23B

Stock Market
Equities
CRSP Stock

Secure and Increase the Performance of your Investments with our Team of Experts at your Side Secure my Investments

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '31670652');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });